Evidence map›Paper›PMID 36494499›Full record

ArticleCommunications biology2022

Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response.

Ksenia V Zornikova, Alexandra Khmelevskaya, Savely A Sheetikov, Dmitry O Kiryukhin, Olga V Shcherbakova, Aleksei Titov, Ivan V Zvyagin, Grigory A Efimov

Abstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The molecular mechanisms of CD8Frontiers in immunology · 2024
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ksenia V ZornikovaNational Medical Research Center for Hematology, Moscow, Russia.ORCID 0000-0002-9568-2109
Alexandra KhmelevskayaNational Medical Research Center for Hematology, Moscow, Russia.
Savely A SheetikovNational Medical Research Center for Hematology, Moscow, Russia.
Dmitry O KiryukhinNational Medical Research Center for Hematology, Moscow, Russia.
Olga V ShcherbakovaNational Medical Research Center for Hematology, Moscow, Russia.
Aleksei TitovNational Medical Research Center for Hematology, Moscow, Russia.
Ivan V ZvyaginDepartment of Genomics of Adaptive Immunity, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.ORCID 0000-0002-1769-9116
Grigory A EfimovNational Medical Research Center for Hematology, Moscow, Russia. efimov.g@blood.ru.ORCID 0000-0001-7129-6062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cells play a pivotal role in reducing disease severity during SARS-CoV-2 infection and formation of long-term immune memory. We studied 50 COVID-19 convalescent patients and found that T cell response was induced more frequently and persisted longer than circulating antibodies. We identified 756 clonotypes specific to nine CD8+ T cell epitopes. Some epitopes were recognized by highly similar public clonotypes. Receptors for other epitopes were extremely diverse, suggesting alternative modes of recognition. We tracked persistence of epitope-specific response and individual clonotypes for a median of eight months after infection. The number of recognized epitopes per patient and quantity of epitope-specific clonotypes decreased over time, but the studied epitopes were characterized by uneven decline in the number of specific T cells. Epitopes with more clonally diverse TCR repertoires induced more pronounced and durable responses. In contrast, the abundance of specific clonotypes in peripheral circulation had no influence on their persistence.

Indexed as

COVID-19SARS-CoV-2CD8-Positive T-LymphocytesClone CellsEpitopes, T-LymphocyteHumansEpitopes, T-Lymphocyte

Identifiers

PMID36494499
PMCPMC9734123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.